Date: 2016-11-29
Type of information: Completion of the trial
phase: 1b
Announcement: completion of the trial
Company: Oramed Pharmaceuticals (Israel)
Product: ORMD-0901 (oral exenatide)
Action mechanism: hormone/peptide. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that stimulates the secretion of insulin from the pancreas. Exenatide, a GLP-1 analog, is currently marketed in injectable form only, and is indicated for treatment of type 2 diabetes. Exenatide induces insulin release at increased glucose levels and causes a feeling of satiety, which results in reduced food intake and weight loss. Oramed’s oral GLP-1 analog capsule based on the company’s POD™ technology could significantly increase compliance and become a valuable tool in the treatment of diabetes.
Disease: type 2 diabetes
Therapeutic area: Metabolic diseases
Country: USA
Trial details:
Latest
news: • On November 29, 2016, Oramed Pharmaceuticals announced it successfully concluded a Phase Ib study of ORMD-0901, the Company’s proprietary oral GLP-1 analog. The Phase Ib study on type 2 diabetic patients showed ORMD-0901 to be safe and well tolerated, having no serious adverse events, adverse events or abnormal laboratory findings during the study. In addition, the active oral GLP-1 arms of the study showed encouraging trending efficacy.
